idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Supportive Therapy

  • Supportive measures in patients with acute exacerbation of idiopathic pulmonary fibrosis should include relief of dyspnea & provision of supplemental oxygen

Anti-Acid Therapy

  • Acid aspiration & gastroesophageal reflux/gastroesophageal reflux disease causing acute exacerbation of idiopathic pulmonary fibrosis may be treated with antacids (ie proton pump inhibitors, histamine-2 blocker receptor antagonists)
    • May help reduce the risk for microaspiration-associated lung injury 
  • Stress ulcer prophylaxis guidelines must be followed

Antibiotics

  • May be considered in idiopathic pulmonary fibrosis patients in acute exacerbation with radiographic findings of overlapping pneumonia
  • If the culture is negative, a 7-day course of antibiotic is recommended

Symptom Control for Cough & Dyspnea

  • Facial cooling with a fan & the use of opioids & anxiolytics may help alleviate refractory cough & dyspnea

Prevention of Venous Thromboembolism (VTE)

  • Venous thromboembolism is common in patients who were hospitalized due to acute exacerbation of idiopathic pulmonary fibrosis & routine measures should be employed

Vaccine

  • Influenza & pneumococcal vaccines should be offered to patients with idiopathic pulmonary fibrosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 18 Sep 2020
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, 3 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.